- VEEV
- IQV
- CRM
Veeva Systems Inc. VEEV raised its fiscal 2027 outlook after second-quarter revenues increased 17.6% year over year to $928 million. Vault CRM adoption and broader commercial execution added another positive signal.
The question is how quickly CRM migrations, newer R&D products and Falcon can extend growth without raising execution risk. Veeva’s guidance points to continued profitability, but several newer initiatives are still early.
VEEV Raises Its Fiscal 2027 Financial Targets
Veeva now expects fiscal 2027 revenues of $3.682-$3.687 billion, subscription revenues of about $3.08 billion and adjusted earnings of roughly $9.21 per share. The revenue outlook implies about 15% growth at the high end.
Management also projects approximately $1.64 billion in non-GAAP operating income, with a roughly 44% non-GAAP operating margin. That combination keeps profitability intact while the company continues investing in product development and artificial intelligence.
Veeva’s Vault CRM Migration Reaches New Milestones
Vault CRM recorded its best quarter to date, with two additional top-20 biopharma selections. Veeva now has commitments from 12 of the top 20, while more than 180 customers are already live on Vault CRM.
The migration can also deepen adoption across Veeva’s Commercial Cloud. Salesforce, Inc. CRM, which competes in CRM and agentic software, reported second-quarter fiscal 2027 revenues of $11.3 billion, up 11% year over year, underscoring the scale of enterprise CRM and AI competition.
VEEV’s Falcon AI Adds a New Growth Avenue
Falcon moves Veeva into agentic labor for workflows such as clinical document processing and safety case intake. Five customers are early adopters, including a top-20 pharma company, and first go-lives are expected in 2026.
Customer interest is running ahead of product readiness. Management said Veeva is currently the rate limiter as it works to prove agent quality, operating processes and human-review controls, making execution more important than near-term Falcon revenues.
Veeva’s R&D Portfolio Broadens the Growth Base
Veeva’s R&D and Quality subscription revenues rose 19% year over year to $419.4 million in the second quarter. Management expects newer products, including EDC, eCOA, RTSM, Safety and LIMS, to become more important as mature applications grow more slowly.
IQVIA Holdings Inc. IQV provides another life-sciences technology comparison. Its second-quarter 2026 revenues rose 8.7% to $4.37 billion, with both Commercial Solutions and R&D Solutions expanding, highlighting continued spending across life-sciences data, technology and research workflows.
